Efficacy of a Dengue Vaccine Candidate (TAK-003) in Healthy Children and Adolescents 2 Years after Vaccination

BACKGROUND: Takeda’s dengue vaccine is under evaluation in an ongoing phase 3 efficacy study; we present a 2-year update. METHODS: Children (20 099, 4–16 years old) were randomized to receive 2 doses of TAK-003 or placebo 3 months apart and are under surveillance to detect dengue by serotype-specifi...

Descripción completa

Detalles Bibliográficos
Autores principales: López-Medina, Eduardo, Biswal, Shibadas, Saez-Llorens, Xavier, Borja-Tabora, Charissa, Bravo, Lulu, Sirivichayakul, Chukiat, Vargas, Luis Martinez, Alera, Maria Theresa, Velásquez, Hector, Reynales, Humberto, Rivera, Luis, Watanaveeradej, Veerachai, Rodriguez-Arenales, Edith Johana, Yu, Delia, Espinoza, Felix, Dietze, Reynaldo, Fernando, Lak Kumar, Wickramasinghe, Pujitha, Duarte Moreira, Edson, Fernando, Asvini D, Gunasekera, Dulanie, Luz, Kleber, da Cunha, Rivaldo Venâncio, Tricou, Vianney, Rauscher, Martina, Liu, Mengya, LeFevre, Inge, Wallace, Derek, Kosalaraksa, Pope, Borkowski, Astrid
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Major Articles and Brief Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9071282/
https://www.ncbi.nlm.nih.gov/pubmed/33319249
http://dx.doi.org/10.1093/infdis/jiaa761

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9071282/
https://www.ncbi.nlm.nih.gov/pubmed/33319249
http://dx.doi.org/10.1093/infdis/jiaa761

Ejemplares similares